Archives for May 2015

May 2015 - Page 5 of 22 - Money Morning - Only the News You Can Profit From

Is GDX Stock a Buy?

Many gold-mining stocks have enjoyed healthy year-to-date gains. GDX stock – also known as the Market Vectors Gold Miners ETF (NYSE Arca: GDX) is up 5.4% in 2015, compared to the Dow's 1.3% gain.

Driving gold miners' advances this year are the same drivers of the precious metal. They include Middle East tensions, devalued currencies, loose global central bank monetary policies, and hopes of a later-rather-than-sooner interest rate hike from the U.S. Federal Reserve.

So will GDX stock keep rising? Here's a look...

This New Junior Gold Miners ETF Will Outpace Its Competitors

A new gold miners ETF launched by Sprott Asset Management focuses on junior miners – and it's garnering considerable attention.

This new gold miners ETF is perfect for precious metals investors. Selective stock picking is more relevant than ever in this space, as the cyclical bear has pummeled precious metals.

This deliberate approach to designing the new Sprott Junior Gold Miners ETF is likely to make it a clear cut above its competition.

Here's a look at the APLS ETF Trust Sprott Junior Gold Miners ETF (NYSE Arca: SGDJ).

TWC, CHTR, and AAPL Are the Top Stocks to Watch Today

U.S. stock futures forecast a 20-point dip from Friday's close. The U.S. markets were closed on Monday in observance of Memorial Day.

On Friday, the DJIA Index was flat as investors reacted negatively after Federal Reserve Chair Janet Yellen suggested the central bank is on pace to raise interest rates in 2015 and that the process was expected to be gradual.

Here are the top earnings reports, the top stock market news, and stocks to watch today based on today's market moves...

"21st Century Cures" Could Revolutionize Biotech

No one is thrilled with the way new drugs and medical devices come to market in the U.S. – not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

But new regulations on the table could change everything for biotech investors and critically ill patients...

A Money Murder Mystery: Who Killed the Stock Market?

Liquidity, the "life blood" that allows the world's capital markets to function, has been murdered.

It was choked violently in the bond market by the gloved hands of its erstwhile babysitter – the broker-dealers – but it bled to death in the stock market from a thousand cuts.

We should be afraid. The lurking henchmen who worked as lookouts on "the job" are the very regulators and guardians of the stock and bond markets who should've stopped it.

Worse, they don't understand their own crime.

That's scary enough, but what's more frightening is how the wheels of both the stock and bond markets could seize and come to a shredding halt at any time.

Investors who don't want to be murder victims need to examine the evidence.

Here it is, in black and white with red all over...

The Chinese and U.S. Economies Are Bubble-Thin

The Shanghai Composite Index soared by 8% last week to its highest level since 2008 and is up about 130% over the last year.

The Shenzhen Composite Index jumped by 12% last week and is up 166% over the same period and is now trading at 66x earnings according to Bloomberg, three times the level of the Shanghai Index.

How do you spell "bubble" in Chinese?

Full story here...

Time Warner Cable (TWC) Stock Could Gain 35% from a Merger

TWC stock has big gains sitting in front of it as suitors line up in a bidding war to acquire Time Warner Cable Inc. (NYSE: TWC).

TWC stock is up 20% over the past year and 79% over the past two years. Now TWC shareholders are looking at gains of anywhere from 15% to 35%, depending on which company succeeds in pulling off the deal.

Here's a closer look at each of the companies in the hunt for Time Warner Cable...